Tenaya Therapeutics, Inc.

TNYA Nasdaq CIK: 0001858848

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
Phone 415-865-2066
Fiscal Year End 1231
EIN 813789973

Financial Overview

FY2025

$146.92M
Total Assets
$27.09M
Total Liabilities
$100.55M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 11, 2026 View on SEC
10-K Annual financial report March 11, 2026 View on SEC
8-K Current report of material events March 5, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 26, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 12, 2026 View on SEC

Annual Reports

10-K March 11, 2026
  • Clinical-stage biotechnology company focused on developing innovative treatments for heart disease.
  • Advancing a pipeline of drug candidates using cutting-edge approaches like gene therapy and small molecules.
View Analysis

Insider Trading

STRONG SELL 4 insiders 21 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.